Status:
COMPLETED
A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepre...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and women, 18 years or older
- Experiencing Major Depressive Disorder with a duration of minimally 8 weeks.
- Treatment history of an inadequate response to at least one and no more than four antidepressants
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
1002 Patients enrolled
Trial Details
Trial ID
NCT00095745
Start Date
September 1 2004
End Date
November 1 2007
Last Update
November 8 2013
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Mesa, Arizona, United States
2
Local Institution
Peoria, Arizona, United States
3
Local Institution
Beverly Hills, California, United States
4
Local Institution
Burbank, California, United States